{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:41:47Z","timestamp":1791268907541,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI22C2068"],"award-info":[{"award-number":["HI22C2068"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2023R1A2C2007839"],"award-info":[{"award-number":["2023R1A2C2007839"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["RS-2023-00214425"],"award-info":[{"award-number":["RS-2023-00214425"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ymthe.2024.03.029","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T13:18:20Z","timestamp":1711372700000},"page":"1805-1816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["In\u00a0vitro and in\u00a0vivo validation of the antiviral effect of hCypA against SARS-CoV-2 via binding to the RBD of spike protein"],"prefix":"10.1016","volume":"32","author":[{"given":"Woo-Ri","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gna","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiho","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-2284","authenticated-orcid":false,"given":"Ji-Young","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.03.029_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ymthe.2024.03.029_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-020-03332-4","article-title":"Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain","volume":"24","author":"Garc\u00eda-Salido","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.ymthe.2024.03.029_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd2071","article-title":"Phenotype and kinetics of SARS-CoV-2\u2013specific T\u00a0cells in COVID-19 patients with acute respiratory distress syndrome","volume":"5","author":"Weiskopf","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2024.03.029_bib4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.03.029_bib5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ijbiomac.2021.08.076","article-title":"SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review","volume":"188","author":"Fathizadeh","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ymthe.2024.03.029_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109721","article-title":"Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19","volume":"74","author":"Poduri","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ymthe.2024.03.029_bib7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann. Med."},{"key":"10.1016\/j.ymthe.2024.03.029_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100794","article-title":"An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment","volume":"59","author":"Dro\u017cd\u017cal","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.ymthe.2024.03.029_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ymthe.2024.03.029_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jiab361","article-title":"Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model","volume":"224","author":"Abdelnabi","year":"2021","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2024.03.029_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105492","article-title":"Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model","volume":"209","author":"Johnson","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ymthe.2024.03.029_bib12","article-title":"A randomized clinical trial of regdanvimab in high-risk patients with mild-to-moderate coronavirus disease 2019","volume":"9","author":"Kim","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.ymthe.2024.03.029_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/13543784.2022.2030310","article-title":"Monoclonal antibody therapies in the management of SARS-CoV-2 infection","volume":"31","author":"Miguez-Rey","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ymthe.2024.03.029_bib14","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3390\/ph14121272","article-title":"Monoclonal antibodies against SARS-CoV-2: current scenario and future perspectives","volume":"14","author":"Quiros-Roldan","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ymthe.2024.03.029_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2024.03.029_bib16","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.it.2020.10.004","article-title":"Mechanisms of SARS-CoV-2 transmission and pathogenesis","volume":"41","author":"Harrison","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2024.03.029_bib17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.ymthe.2024.03.029_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"nature"},{"key":"10.1016\/j.ymthe.2024.03.029_bib19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.03.029_bib20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41423-020-0458-z","article-title":"Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies","volume":"17","author":"Yi","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ymthe.2024.03.029_bib21","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.1038\/cddis.2013.410","article-title":"Cyclophilin A: a key player for human disease","volume":"4","author":"Nigro","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2024.03.029_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002331","article-title":"The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors","volume":"7","author":"Pfefferle","year":"2011","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2024.03.029_bib23","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/337476a0","article-title":"Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins","volume":"337","author":"Fischer","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.03.029_bib24","article-title":"Cyclophilin A-mediated mitigation of coronavirus SARS-CoV-2","volume":"8","author":"Sekhon","year":"2022","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.03.029_bib25","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1038\/nprot.2007.459","article-title":"Detecting protein\u2013protein interactions by far western blotting","volume":"2","author":"Wu","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2024.03.029_bib26","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.2147\/IDR.S321915","article-title":"Abnormal indexes of liver and kidney injury markers predict severity in COVID-19 patients","volume":"14","author":"Qu","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.ymthe.2024.03.029_bib27","series-title":"The Mouse in Biomedical Research","first-page":"171","article-title":"Clinical chemistry of the laboratory mouse","author":"Quimby","year":"2007"},{"key":"10.1016\/j.ymthe.2024.03.029_bib28","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1111\/all.14364","article-title":"Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19","volume":"75","author":"Azkur","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.ymthe.2024.03.029_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41392-020-0211-1","article-title":"Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients","volume":"5","author":"Xu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2024.03.029_bib30","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41467-021-21310-4","article-title":"Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections","volume":"12","author":"B\u00e9nard","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.03.029_bib31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1096\/fj.06-7227rev","article-title":"Resolution of inflammation: state of the art, definitions and terms","volume":"21","author":"Serhan","year":"2007","journal-title":"FASEB J. official Publ. Fed. Am. Societies Exp. Biol."},{"key":"10.1016\/j.ymthe.2024.03.029_bib32","first-page":"930","article-title":"Short technical reports. Effects of lipopolysaccharide on transfection efficiency in eukaryotic cells","volume":"19","author":"Weber","year":"1995","journal-title":"BioTechniques"},{"key":"10.1016\/j.ymthe.2024.03.029_bib33","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0002-9440(10)63715-7","article-title":"Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction","volume":"164","author":"Kim","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2024.03.029_bib34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s42003-020-0988-z","article-title":"High-content fluorescence imaging with the metabolic flux assay reveals insights into mitochondrial properties and functions","volume":"3","author":"Little","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ymthe.2024.03.029_bib35","first-page":"1","article-title":"Cyclophilin A: a key factor in virus replication and potential target for anti-viral therapy","volume":"21","author":"Dawar","year":"2017","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.ymthe.2024.03.029_bib36","doi-asserted-by":"crossref","first-page":"19970","DOI":"10.1073\/pnas.0908837106","article-title":"Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor","volume":"106","author":"Wu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.03.029_bib37","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","article-title":"SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function","volume":"21","author":"Winkler","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2024.03.029_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ymthe.2024.03.029_bib39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Epidemiol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624001709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624001709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:23:49Z","timestamp":1776803029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624001709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1525001624001709"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.03.029","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vitro and in\u00a0vivo validation of the antiviral effect of hCypA against SARS-CoV-2 via binding to the RBD of spike protein","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}